share_log

Chison Medical Technologies' (SHSE:688358) Profits May Not Reveal Underlying Issues

Chison Medical Technologies' (SHSE:688358) Profits May Not Reveal Underlying Issues

Chison Medical Technologies(上海證券交易所代碼:688358)的利潤可能不會揭示潛在問題
Simply Wall St ·  04/26 06:39

Chison Medical Technologies Co., Ltd. (SHSE:688358) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weakening the foundations of those good profit numbers.

奇生醫療科技股份有限公司(SHSE: 688358)剛剛發佈了一份穩健的收益報告,該股表現出一定的走強。儘管如此,我們的分析表明,有一些因素削弱了這些良好利潤數字的基礎。

earnings-and-revenue-history
SHSE:688358 Earnings and Revenue History April 25th 2024
SHSE: 688358 2024 年 4 月 25 日的收益和收入歷史記錄

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

Importantly, our data indicates that Chison Medical Technologies' profit received a boost of CN¥13m in unusual items, over the last year. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. If Chison Medical Technologies doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

重要的是,我們的數據表明,奇生醫療科技的不尋常項目利潤比去年增加了1300萬元人民幣。我們不能否認更高的利潤通常會讓我們感到樂觀,但如果利潤是可持續的,我們更願意這樣做。當我們計算數千家上市公司的數字時,我們發現,特定年份中不尋常的項目所帶來的提振通常不會在第二年重演。而且,畢竟,這正是會計術語的含義。如果奇森醫療科技沒有看到這種捐款重演,那麼在其他條件相同的情況下,我們預計其本年度的利潤將下降。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Chison Medical Technologies' Profit Performance

我們對奇森醫療科技盈利表現的看法

We'd posit that Chison Medical Technologies' statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Chison Medical Technologies' statutory profits are better than its underlying earnings power. Nonetheless, it's still worth noting that its earnings per share have grown at 36% over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. Case in point: We've spotted 1 warning sign for Chison Medical Technologies you should be aware of.

我們認爲,由於這個很大的不尋常項目,奇森醫療科技的法定收入並不能完全反映持續的生產力。因此,我們認爲奇森醫療科技的法定利潤可能好於其基礎盈利能力。儘管如此,仍然值得注意的是,其每股收益在過去三年中增長了36%。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。考慮到這一點,除非我們對風險有透徹的了解,否則我們不會考慮投資股票。一個很好的例子:我們發現了奇森醫療科技的1個警告信號,你應該注意。

Today we've zoomed in on a single data point to better understand the nature of Chison Medical Technologies' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了單個數據點,以更好地了解奇生醫療科技利潤的性質。但是,還有很多其他方法可以讓你對公司的看法。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論